Erman Akkus: Immunotherapy at the end-of-life
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“Immunotherapy at the end-of-life
– Immunotherapy initiation within 1 month of death increased over time
– 242,371 patients, metastatic melanoma, NSCLC, RCC
– 29.3% received immunotherapy
– Immunotherapy initiation within 1 month of death increased over the study period:
– Melanoma: from 0.8% to 4.3%
– NSCLC: 0.9% to 3.2%
– RCC: 0.5% to 2.6%
– Nonacademic or very low-volume center> higher end-of-life IO initiation
Questions:
– Is the reason about being less toxic than chemo so that physicians choose IO at the end-of-life?
– Would there be any possibility that IO-related hyperprogression causes more death so that it seems like it is initiated within 1 month of death?”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023